Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. The Anaplastic Astrocytoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

Anaplastic Astrocytoma Pipeline Drugs Market Segmentation by Targets

The key targets of the Anaplastic Astrocytoma pipeline drugs market are Serine/Threonine Protein Kinase B Raf, Receptor Type Tyrosine Protein Kinase FLT3, Baculoviral IAP Repeat Containing Protein 5, Cells Expressing Vimentin, Cyclin Dependent Kinase 1, Cyclin Dependent Kinase 2, Cyclin Dependent Kinase 4, and Cyclin Dependent Kinase 6.

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Targets

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Targets

For more target insights into the Anaplastic Astrocytoma pipeline drugs market, download a free report sample

Anaplastic Astrocytoma Pipeline Drugs Market Segmentation by Mechanisms of Action

The key mechanisms of action of the Anaplastic Astrocytoma pipeline drugs market are Serine/Threonine Protein Kinase B Raf Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cyclin Dependent Kinase 1 Inhibitor, Cyclin Dependent Kinase 2 Inhibitor, Cyclin Dependent Kinase 4 Inhibitor, and Cyclin Dependent Kinase 6 Inhibitor.

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Mechanisms of Action

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Mechanisms of Action

For more mechanisms of action insights into the Anaplastic Astrocytoma pipeline drugs market, download a free report sample

Anaplastic Astrocytoma Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Anaplastic Astrocytoma pipeline drugs market are Oral, Intravenous, Intratumor, Intracerebral, Intradermal, Subcutaneous, Topical, and Ophthalmic.

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Routes of Administration

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Anaplastic Astrocytoma pipeline drugs market, download a free report sample

Anaplastic Astrocytoma Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the Anaplastic Astrocytoma pipeline drugs market are small molecule, oncolytic virus, monoclonal antibody, cell therapy, gene therapy, subunit vaccine, DNA vaccine, and gene-modified cell therapy.

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Molecule Types

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Anaplastic Astrocytoma pipeline drugs market, download a free report sample

Anaplastic Astrocytoma Pipeline Drugs Market - Competitive Landscape

Some of the leading companies in the Anaplastic Astrocytoma pipeline drugs market are Bayer AG, Aettis Inc, Candel Therapeutics Inc, Cothera Bioscience Pty Ltd, Mustang Bio Inc, Nascent Biotech Inc, and Novartis AG.

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Companies

Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Companies

To know more about the companies in the Anaplastic Astrocytoma pipeline drugs market, download a free report sample

Anaplastic Astrocytoma Pipeline Drugs Market Report Overview

Key Targets Serine/Threonine Protein Kinase B Raf, Receptor Type Tyrosine Protein Kinase FLT3, Baculoviral IAP Repeat Containing Protein 5, Cells Expressing Vimentin, Cyclin Dependent Kinase 1, Cyclin Dependent Kinase 2, Cyclin Dependent Kinase 4, and Cyclin Dependent Kinase 6
Key Mechanisms of Action Serine/Threonine Protein Kinase B Raf Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cyclin Dependent Kinase 1 Inhibitor, Cyclin Dependent Kinase 2 Inhibitor, Cyclin Dependent Kinase 4 Inhibitor, and Cyclin Dependent Kinase 6 Inhibitor
Key Routes of Administration Oral, Intravenous, Intratumor, Intracerebral, Intradermal, Subcutaneous, Topical, and Ophthalmic
Key Molecule Types Small Molecule, Oncolytic Virus, Monoclonal Antibody, Cell Therapy, Gene Therapy, Subunit Vaccine, DNA Vaccine, and Gene-Modified Cell Therapy
Leading Companies Bayer AG, Aettis Inc, Candel Therapeutics Inc, Cothera Bioscience Pty Ltd, Mustang Bio Inc, Nascent Biotech Inc, and Novartis AG

Scope 

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

A. Menarini Industrie Farmaceutiche Riunite Srl
AbbVie Inc
Aettis Inc
AngioChem Inc
Apexigen Inc
Bayer AG
Berg LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Candel Therapeutics Inc
CDG Therapeutics Inc
Cellix Bio Pvt Ltd
Chimerix Inc
Cothera Bioscience Pty Ltd
Curis Inc
Everfront Biotech Inc
Fore Biotherapeutics Inc
Geneos Therapeutics Inc
Ipsen SA
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Merck KGaA
MimiVax LLC
Mustang Bio Inc
Nascent Biotech Inc
Novartis AG
OncoSynergy Inc
Orbus Therapeutics Inc
Orphelia Pharma SAS
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
TheraBiologics Inc
Wayshine Biopharma Inc
Wuhan Binhui Biotechnology Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Anaplastic Astrocytoma – Overview

Anaplastic Astrocytoma – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Anaplastic Astrocytoma – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Anaplastic Astrocytoma – Companies Involved in Therapeutics Development

A. Menarini Industrie Farmaceutiche Riunite Srl

AbbVie Inc

Aettis Inc

AngioChem Inc

Apexigen Inc

Bayer AG

Berg LLC

Boehringer Ingelheim International GmbH

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Candel Therapeutics Inc

CDG Therapeutics Inc

Cellix Bio Pvt Ltd

Chimerix Inc

Cothera Bioscience Pty Ltd

Curis Inc

Everfront Biotech Inc

Fore Biotherapeutics Inc

Geneos Therapeutics Inc

Ipsen SA

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Merck KGaA

MimiVax LLC

Mustang Bio Inc

Nascent Biotech Inc

Novartis AG

OncoSynergy Inc

Orbus Therapeutics Inc

Orphelia Pharma SAS

Otsuka Pharmaceutical Co Ltd

Pfizer Inc

PTC Therapeutics Inc

TheraBiologics Inc

Wayshine Biopharma Inc

Wuhan Binhui Biotechnology Co Ltd

Anaplastic Astrocytoma – Drug Profiles

afatinib dimaleate – Drug Profile

Product Description

Mechanism Of Action

aglatimagene besadenovec – Drug Profile

Product Description

Mechanism Of Action

BAY-1436032 – Drug Profile

Product Description

Mechanism Of Action

BAY-2666605 – Drug Profile

Product Description

Mechanism Of Action

Cellular Immunotherapy for Oncology – Drug Profile

Product Description

Mechanism Of Action

Cellular Immunotherapy for Oncology – Drug Profile

Product Description

Mechanism Of Action

Cellular Immunotherapy for Oncology – Drug Profile

Product Description

Mechanism Of Action

CLXONC-643 – Drug Profile

Product Description

Mechanism Of Action

dabrafenib mesylate – Drug Profile

Product Description

Mechanism Of Action

eflornithine – Drug Profile

Product Description

Mechanism Of Action

fimepinostat – Drug Profile

Product Description

Mechanism Of Action

FORE-8394 – Drug Profile

Product Description

Mechanism Of Action

futibatinib – Drug Profile

Product Description

Mechanism Of Action

G-207 – Drug Profile

Product Description

Mechanism Of Action

GENPV-001 – Drug Profile

Product Description

Mechanism Of Action

irinotecan hydrochloride – Drug Profile

Product Description

Mechanism Of Action

M-032 – Drug Profile

Product Description

Mechanism Of Action

MB-108 – Drug Profile

Product Description

Mechanism Of Action

MB-110 – Drug Profile

Product Description

Mechanism Of Action

OH-2 – Drug Profile

Product Description

Mechanism Of Action

ON-01 – Drug Profile

Product Description

Mechanism Of Action

ONC-206 – Drug Profile

Product Description

Mechanism Of Action

OS-2966 – Drug Profile

Product Description

Mechanism Of Action

P-28 – Drug Profile

Product Description

Mechanism Of Action

paclitaxel trevatide – Drug Profile

Product Description

Mechanism Of Action

palbociclib – Drug Profile

Product Description

Mechanism Of Action

paxalisib – Drug Profile

Product Description

Mechanism Of Action

pritumumab – Drug Profile

Product Description

Mechanism Of Action

regorafenib – Drug Profile

Product Description

Mechanism Of Action

ribociclib succinate – Drug Profile

Product Description

Mechanism Of Action

selinexor – Drug Profile

Product Description

Mechanism Of Action

SL-701 – Drug Profile

Product Description

Mechanism Of Action

sorafenib tosylate – Drug Profile

Product Description

Mechanism Of Action

sotigalimab – Drug Profile

Product Description

Mechanism Of Action

SurVaxM – Drug Profile

Product Description

Mechanism Of Action

TBX.OncV NSC – Drug Profile

Product Description

Mechanism Of Action

telaglenastat hydrochloride – Drug Profile

Product Description

Mechanism Of Action

temozolomide – Drug Profile

Product Description

Mechanism Of Action

tepotinib hydrochloride – Drug Profile

Product Description

Mechanism Of Action

trotabresib – Drug Profile

Product Description

Mechanism Of Action

ubidecarenone – Drug Profile

Product Description

Mechanism Of Action

unesbulin – Drug Profile

Product Description

Mechanism Of Action

veliparib ER – Drug Profile

Product Description

Mechanism Of Action

WSD-0922 – Drug Profile

Product Description

Mechanism Of Action

z-90099 – Drug Profile

Product Description

Mechanism Of Action

zotiraciclib citrate – Drug Profile

Product Description

Mechanism Of Action

Anaplastic Astrocytoma – Dormant Projects

Anaplastic Astrocytoma – Discontinued Products

Anaplastic Astrocytoma – Product Development Milestones

Featured News & Press Releases

Jan 19, 2022: Orbus Therapeutics’ phase 3 Eflornithine STELLAR study reaches full patient enrollment

Sep 28, 2021: Orbus Therapeutics granted European patent for method of use for Eflornithine

Mar 02, 2021: Orbus Therapeutics announces positive outcome of pre-planned interim futility analysis for phase 3 Eflornithine STELLAR study

Dec 23, 2020: Orbus Therapeutics receives U.S. Patent for Eflornithine formulations

Jul 10, 2020: Geneos Therapeutics announces first patient dosed with its DNA-based, neoantigen-targeting personalized vaccine technology

Feb 04, 2020: STELLAR clinical trial of eflornithine to enrol brain tumour patients

May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019

Jun 05, 2017: Orbus Therapeutics Announces ASCO Study Design Presentation of Pivotal Clinical Trial in Patients with Late-Stage Brain Cancer

Sep 26, 2016: Orbus Therapeutics Announces Enrollment of First Patient in Phase 3 Trial in Late-Stage Brain Cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Anaplastic Astrocytoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Anaplastic Astrocytoma – Dormant Projects, 2022

Anaplastic Astrocytoma – Dormant Projects, 2022 (Contd..1)

Anaplastic Astrocytoma – Dormant Projects, 2022 (Contd..2)

Anaplastic Astrocytoma – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Anaplastic Astrocytoma, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.